Related Experiment Videos
[Effect of ticlopidine and dipyridamole on platelet aggregation and count in patients with chronic stable angina
J A Ramires1, A de P Mansur, J R Martins
1Instituto do Coraçăo do Hospital das Clínicas, FMUSP.
Insights
Ticlopidine significantly inhibits platelet aggregation more effectively than dipyridamole in coronary artery disease patients. Platelet counts remained unchanged, suggesting ticlopidine as a potential cardiovascular event preventative.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Stable coronary artery disease (CAD) requires effective antiplatelet therapy.
- Platelet aggregation plays a critical role in atherothrombotic events in CAD.
Purpose of the Study:
- To compare the antiplatelet effects of ticlopidine and dipyridamole.
- To evaluate the impact on platelet count and aggregation in stable CAD patients.
Main Methods:
- Eighty patients with stable CAD were randomized into two groups (n=40 each).
- One group received ticlopidine, the other dipyridamole.
- Platelet count and aggregation were assessed at baseline, week 1, and week 4.
Main Results:
- Ticlopidine demonstrated significantly higher inhibition of spontaneous, ADP-, and adrenalin-induced platelet aggregation (82.5%, 72.5%, 67.5%) compared to dipyridamole (40%, 30%, 27.5%) (p < 0.001).
- No significant changes in platelet counts were observed in either treatment group.
Conclusions:
- Ticlopidine exhibits superior efficacy in inhibiting platelet aggregation compared to dipyridamole.
- Ticlopidine may be a preferred option for preventing cardiovascular events in patients with stable CAD.
Purpose:
To compare the ticlopidine and dipyridamole effects on platelets count and aggregation in patients with stable coronary artery disease.
Patients And Methods:
Eighty patients with stable coronary artery disease and mean of 58.3 +/- 5.8 years were studied. They were divided into two equal groups of 40 patients and each one treated with ticlopidine or dipyridamole. Platelets count and aggregation were examined before treatment and at first and fourth weeks of treatment.
Results:
At the end of fourth week of treatment, spontaneous, induced by ADP or by adrenalin platelet aggregation inhibition was observed, respectively, in 82.5%, 72.5% e 67.5% of the patients in ticlopidine group. The spontaneous, induced by ADP or by adrenalin, platelet aggregation inhibition in the patients of dipyridamole group was, respectively, 40%, 30% e 27.5% (p less than 0.001). The platelets count did not change in both groups.
Conclusion:
The ticlopidine effect is much more evident in platelet aggregation inhibition than dipyridamole, and maybe a choice in the prevention of cardiovascular events.